Julie Poliquin
About Julie Poliquin
Julie Poliquin is the Manager of Clinical Site Monitors at Bristol-Myers Squibb in Montreal, Canada, with over 20 years of experience in clinical research and site monitoring.
Title and Current Role
Julie Poliquin currently holds the title of Manager, Clinical Site Monitors at Bristol-Myers Squibb in the Montreal, Canada Area. In this role, she oversees the activities and performance of clinical site monitors, ensuring the effective execution of clinical trials and adherence to regulatory standards.
Education And Expertise
Julie Poliquin studied at Université de Montréal, where she focused on Biologie Moléculaire. She earned her M.Sc., which laid the foundation for her extensive career in clinical research and site monitoring. Her educational background has equipped her with a deep understanding of molecular biology, critical for her roles in clinical trial management and quality assurance.
Professional Background
Julie Poliquin has over 20 years of experience in clinical research and site monitoring. She started her career as a Quality Assurance Auditor at MDS Pharma Services from 1999 to 2001. Following this, she served as a CRA at Quintiles from 2001 to 2003. Julie then joined Bristol-Myers Squibb and worked in various roles culminating in her current managerial position, accumulating over 18 years of experience at the company.
Career Progression at Bristol-Myers Squibb
Julie's career at Bristol-Myers Squibb began in 2003 when she took on the role of Senior Clinical Site Manager. She held this position for seven years before transitioning to Senior Clinical Site Monitor in 2010, a role she held for eight years. Her extensive experience and expertise in these roles led to her promotion to Manager, Clinical Site Monitors, where she now oversees the clinical monitoring team.
Experience in Quality Assurance
Julie Poliquin possesses a strong background in quality assurance, gained during her tenure at MDS Pharma Services as a Quality Assurance Auditor from 1999 to 2001. This experience has been integral to her subsequent roles in clinical research and site monitoring, ensuring adherence to regulatory standards and the continual improvement of clinical trial processes.